Press Releases
April 18, 2025
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satietyBremelanotide matched or exceeded tirzepatide in appetite suppressionLow-dose bremelanotide helped prevent appetite rebound
